<DOC>
	<DOCNO>NCT01866111</DOCNO>
	<brief_summary>This multicenter , double-blind , randomize , placebo-controlled dose response study , 8-week prospective baseline 18 week double-blind treatment period ( include 6-week titration phase 12 week maintenance phase ) , follow 3-week blinded study drug taper period ( subject leave study ) 2-week blinded conversion period ( subject participate open-label extension ) . The primary objective study determine effective dose range YKP3089 adjunctive therapy treatment partial seizure . The trial also evaluate safety tolerability YKP3089 partial epilepsy population .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Placebo-Controlled , Phase 2 Trial YKP3089 Adjunctive Therapy Subjects With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>Weight least 40 kg A diagnosis partial epilepsy accord International League Against Epilepsy 's Classification Epileptic Seizures . Diagnosis establish clinical history electroencephalogram ( EEG ) consistent localization relate epilepsy ; normal interictal EEGs allow provide subject meet diagnosis criterion ( ie , clinical history ) Have uncontrolled partial seizure despite treat least 1 AED within approximately last 2 year During 8week baseline period , subject must least 8 partial seizure include simple partial seizure motor component , complex partial seizure , secondarily generalize seizure without seizurefree interval great 25 day time 8 week baseline . Subjects must least 3 partial seizure two consecutive 4week segment baseline period Currently stable antiepileptic treatment regimen . A history nonepileptic psychogenic seizure Presence nonmotor simple partial seizure primary generalized epilepsy Presence previous history LennoxGastaut syndrome An active CNS infection , demyelinate disease , degenerative neurologic disease , CNS disease deem progressive course study may confound interpretation study result Any clinically significant psychiatric illness , psychological , behavioral problem , opinion Investigator , would interfere subject 's ability participate study History alcoholism , drug abuse , drug addiction within past 2 year History status epilepticus within 3 month Visit 1 A `` yes '' answer Question 1 2 CSSRS ( Baseline/Screening version ) Ideation Section past 6 month `` yes '' answer Suicidal Behavior Questions past 2 year More 1 lifetime suicide attempt Participation trial involve investigational product device within 30 day screen ( longer , require local regulation ) A history previous exposure YKP3089</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>